TCL電子孵化的雷鳥創新發布首款雙目全綵MicroLED光波導AR眼鏡
格隆匯10月15日丨AR新鋭公司雷鳥創新今日正式發佈雷鳥智能眼鏡先鋒版。據瞭解,這是業內首款雙目全綵MicroLED全息光波導AR眼鏡。有觀點認為,AR/VR將是繼PC電腦、智能手機之後的下一代計算平台,隨着谷歌、Facebook、字節跳動等科技巨頭的進入有望帶動整個AR/VR產業鏈快速發展。據招商證券報吿顯示,預計到2025年全球AR/VR產業空間將達近兩萬億元,年均增長率約54%。據瞭解,雷鳥創新脱胎於TCL,由雷鳥科技孵化,是一家專注於AR領域的全新創業公司,公司核心團隊來自AR、手機和智屏等領域。此前該團隊打造的XR眼鏡NXTWAER G在韓國、日本、澳大利亞、美國等國家已經開售。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.